The trusted source for
healthcare information and
CONTINUING EDUCATION.
Anti-HER2 Antibody, Trastuzumab in Patients with Recurrent or Refractory Ovarian or Primary Peritoneal Carcinoma with Overexpression | Single Article
$8.00
Product Details
Purchase access to this article; published in Hospital Peer Review.
